The United States Patent and Trademark Office (USPTO) has granted Nestle a patent (US12582627B2) for methods and compositions involving medium chain triglycerides (MCTs) aimed at improving cognitive functions in individuals. The patent details specific daily dosages ranging from 15g to 45g of MCTs, with a particular emphasis on octanoic acid content (51-90 wt%) and a weight ratio of octanoic to decanoic acid (e.g., 60:40). These formulations are intended to enhance episodic memory, executive function, language skills, provide brain energy via ketones, and potentially prevent or treat mild cognitive impairment (MCI), particularly in individuals aged 65 and older.

This patent grant is primarily an intellectual property matter and does not impose direct regulatory obligations on pharmaceutical or food manufacturers. However, it signifies a new development in the therapeutic use of MCTs for cognitive health. Companies operating in the pharmaceutical, nutraceutical, or food sectors, particularly those developing products for cognitive enhancement or age-related cognitive decline, should be aware of this patented technology. While not a compliance mandate, it may influence product development strategies and competitive landscapes in the market for cognitive health supplements and treatments.